{"preliminary_commentary":{"by_channel":{"x_thread":22,"youtube":4,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04394975\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["toripalimab","axitinib"]],"indication":"first-line unresectable or metastatic renal cell carcinoma","name":"RENOTORCH","nct_id":"NCT04394975","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=renotorch-nct04394975. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Toripalimab+axitinib combination therapy. Participants receive Toripalimab 240mg intravenously every 3 weeks plus axitinib 5mg orraly twice daily.","label":"Test group","type":"EXPERIMENTAL"},{"description":"Sunitinib monotherapy. Participants receive sunitinib 50mg orally once daily for 4 weeks and then are off treatent for 2 weeks, or once daily for 2weeks and then are off treatent for 1 week.","label":"Control group","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-04-02","type":"ACTUAL"},"conditions":["Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1"],"enrollment":{"count":421,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Biological : Toripalimab Drug: Axitinib","otherNames":[],"type":"COMBINATION_PRODUCT"},{"name":"sunitinib","otherNames":[],"type":"DRUG"}],"last_update":"2025-11-28","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","official_title":"A Phase III, Randomized, Open-label, Active Controlled, Multicenter Study on Toripalimab Combined With Axitinib Versus Sunitinib Monotheraphy as a First-Line Treatment for Unresectable or Metastatic Renal Cell Carcinoma (RCC)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-04-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"PFS assessed by IRC per RECIST 1.1.","timeFrame":"3 years"}],"references":[{"citation":"Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, He DL, He CH, Xue XY, Ji ZG, Chen H, Zhang S, Liu YP, Zhang XD, Fu C, Xu DF, Qiu MX, Lv JJ, Huang J, Ren XB, Cheng Y, Qin WJ, Zhang X, Zhou FJ, Ma LL, Guo JM, Ding DG, Wei SZ, He Y, Guo HQ, Shi BK, Liu L, Liu F, Hu ZQ, Jin XM, Yang L, Zhu SX, Liu JH, Huang YH, Xu T, Liu B, Sun T, Wang ZJ, Jiang HW, Yu DX, Zhou AP, Jiang J, Luan GD, Jin CL, Xu J, Hu JX, Huang YR, Guo J, Zhai W, Sheng XN. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann Oncol. 2024 Feb;35(2):190-199. doi: 10.1016/j.annonc.2023.09.3108. Epub 2023 Oct 21.","pmid":"37872020","type":"DERIVED"}],"start_date":{"date":"2020-08-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer","url":"https://clinicaltrials.gov/study/NCT04394975"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/renotorch-nct04394975"}